nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—Vismodegib—Sulfasalazine—ankylosing spondylitis	0.594	1	CrCrCtD
Etoricoxib—PTGS2—Sulfasalazine—ankylosing spondylitis	0.0592	0.179	CbGbCtD
Etoricoxib—PTGS2—Triamcinolone—ankylosing spondylitis	0.0592	0.179	CbGbCtD
Etoricoxib—PTGS2—Betamethasone—ankylosing spondylitis	0.0508	0.153	CbGbCtD
Etoricoxib—PTGS2—Dexamethasone—ankylosing spondylitis	0.0296	0.0893	CbGbCtD
Etoricoxib—CYP2C19—Prednisone—ankylosing spondylitis	0.0194	0.0585	CbGbCtD
Etoricoxib—CYP2E1—Dexamethasone—ankylosing spondylitis	0.0193	0.0582	CbGbCtD
Etoricoxib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0154	0.0467	CbGbCtD
Etoricoxib—CYP2C19—Dexamethasone—ankylosing spondylitis	0.0121	0.0365	CbGbCtD
Etoricoxib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0117	0.0354	CbGbCtD
Etoricoxib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.01	0.0303	CbGbCtD
Etoricoxib—CYP3A4—Betamethasone—ankylosing spondylitis	0.01	0.0303	CbGbCtD
Etoricoxib—CYP3A4—Prednisolone—ankylosing spondylitis	0.00991	0.0299	CbGbCtD
Etoricoxib—CYP3A4—Prednisone—ankylosing spondylitis	0.00936	0.0283	CbGbCtD
Etoricoxib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.00919	0.0277	CbGbCtD
Etoricoxib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.00584	0.0176	CbGbCtD
Etoricoxib—PTGS2—Fluocinonide—Methylprednisolone—ankylosing spondylitis	0.00047	0.159	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Dexamethasone—ankylosing spondylitis	0.000463	0.156	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Betamethasone—ankylosing spondylitis	0.000463	0.156	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Triamcinolone—ankylosing spondylitis	0.000452	0.153	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.000284	0.0958	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.000279	0.0943	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.000279	0.0943	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000273	0.0921	CbGdCrCtD
Etoricoxib—Arrhythmia—Dexamethasone—ankylosing spondylitis	0.000123	0.00171	CcSEcCtD
Etoricoxib—Arrhythmia—Betamethasone—ankylosing spondylitis	0.000123	0.00171	CcSEcCtD
Etoricoxib—Pancreatitis—Methotrexate—ankylosing spondylitis	0.000123	0.00171	CcSEcCtD
Etoricoxib—Alopecia—Betamethasone—ankylosing spondylitis	0.000122	0.00169	CcSEcCtD
Etoricoxib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000122	0.00169	CcSEcCtD
Etoricoxib—Angioedema—Triamcinolone—ankylosing spondylitis	0.000121	0.00168	CcSEcCtD
Etoricoxib—Haemoglobin—Prednisone—ankylosing spondylitis	0.000121	0.00167	CcSEcCtD
Etoricoxib—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000121	0.00167	CcSEcCtD
Etoricoxib—Abdominal discomfort—Methotrexate—ankylosing spondylitis	0.00012	0.00167	CcSEcCtD
Etoricoxib—Haemorrhage—Prednisone—ankylosing spondylitis	0.00012	0.00167	CcSEcCtD
Etoricoxib—Erythema—Betamethasone—ankylosing spondylitis	0.00012	0.00167	CcSEcCtD
Etoricoxib—Erythema—Dexamethasone—ankylosing spondylitis	0.00012	0.00167	CcSEcCtD
Etoricoxib—Hallucination—Prednisone—ankylosing spondylitis	0.000119	0.00166	CcSEcCtD
Etoricoxib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000118	0.00164	CcSEcCtD
Etoricoxib—Oedema—Prednisolone—ankylosing spondylitis	0.000117	0.00163	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000117	0.00163	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.000116	0.00162	CcSEcCtD
Etoricoxib—Shock—Prednisolone—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Etoricoxib—Cough—Triamcinolone—ankylosing spondylitis	0.000115	0.0016	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.000114	0.00159	CcSEcCtD
Etoricoxib—Hypertension—Triamcinolone—ankylosing spondylitis	0.000114	0.00158	CcSEcCtD
Etoricoxib—Hypertension—Methylprednisolone—ankylosing spondylitis	0.000114	0.00158	CcSEcCtD
Etoricoxib—Pneumonia—Methotrexate—ankylosing spondylitis	0.000112	0.00156	CcSEcCtD
Etoricoxib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000112	0.00156	CcSEcCtD
Etoricoxib—Eye disorder—Prednisone—ankylosing spondylitis	0.000112	0.00156	CcSEcCtD
Etoricoxib—Anxiety—Methylprednisolone—ankylosing spondylitis	0.000112	0.00155	CcSEcCtD
Etoricoxib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000112	0.00155	CcSEcCtD
Etoricoxib—Infestation—Methotrexate—ankylosing spondylitis	0.000112	0.00155	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000112	0.00155	CcSEcCtD
Etoricoxib—Flushing—Prednisone—ankylosing spondylitis	0.000111	0.00155	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000111	0.00154	CcSEcCtD
Etoricoxib—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00011	0.00153	CcSEcCtD
Etoricoxib—Renal failure—Methotrexate—ankylosing spondylitis	0.00011	0.00152	CcSEcCtD
Etoricoxib—Angioedema—Betamethasone—ankylosing spondylitis	0.00011	0.00152	CcSEcCtD
Etoricoxib—Angioedema—Dexamethasone—ankylosing spondylitis	0.00011	0.00152	CcSEcCtD
Etoricoxib—Stomatitis—Methotrexate—ankylosing spondylitis	0.000109	0.00151	CcSEcCtD
Etoricoxib—Angiopathy—Prednisone—ankylosing spondylitis	0.000109	0.00151	CcSEcCtD
Etoricoxib—Conjunctivitis—Methotrexate—ankylosing spondylitis	0.000109	0.00151	CcSEcCtD
Etoricoxib—Confusional state—Methylprednisolone—ankylosing spondylitis	0.000109	0.00151	CcSEcCtD
Etoricoxib—Immune system disorder—Prednisone—ankylosing spondylitis	0.000108	0.00151	CcSEcCtD
Etoricoxib—Oedema—Triamcinolone—ankylosing spondylitis	0.000108	0.0015	CcSEcCtD
Etoricoxib—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000108	0.0015	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000108	0.00149	CcSEcCtD
Etoricoxib—Arrhythmia—Prednisone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Etoricoxib—Infection—Triamcinolone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Etoricoxib—Infection—Methylprednisolone—ankylosing spondylitis	0.000107	0.00149	CcSEcCtD
Etoricoxib—Haematuria—Methotrexate—ankylosing spondylitis	0.000107	0.00148	CcSEcCtD
Etoricoxib—Shock—Triamcinolone—ankylosing spondylitis	0.000106	0.00147	CcSEcCtD
Etoricoxib—Insomnia—Prednisolone—ankylosing spondylitis	0.000106	0.00147	CcSEcCtD
Etoricoxib—Alopecia—Prednisone—ankylosing spondylitis	0.000106	0.00147	CcSEcCtD
Etoricoxib—Shock—Methylprednisolone—ankylosing spondylitis	0.000106	0.00147	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000106	0.00147	CcSEcCtD
Etoricoxib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000106	0.00147	CcSEcCtD
Etoricoxib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000105	0.00146	CcSEcCtD
Etoricoxib—Mental disorder—Prednisone—ankylosing spondylitis	0.000105	0.00146	CcSEcCtD
Etoricoxib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000105	0.00145	CcSEcCtD
Etoricoxib—Malnutrition—Prednisone—ankylosing spondylitis	0.000105	0.00145	CcSEcCtD
Etoricoxib—Erythema—Prednisone—ankylosing spondylitis	0.000105	0.00145	CcSEcCtD
Etoricoxib—Hypertension—Betamethasone—ankylosing spondylitis	0.000104	0.00144	CcSEcCtD
Etoricoxib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000104	0.00144	CcSEcCtD
Etoricoxib—Anxiety—Dexamethasone—ankylosing spondylitis	0.000102	0.00141	CcSEcCtD
Etoricoxib—Anxiety—Betamethasone—ankylosing spondylitis	0.000102	0.00141	CcSEcCtD
Etoricoxib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000101	0.0014	CcSEcCtD
Etoricoxib—Pain—Prednisolone—ankylosing spondylitis	0.0001	0.00139	CcSEcCtD
Etoricoxib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.0001	0.00139	CcSEcCtD
Etoricoxib—Hepatitis—Methotrexate—ankylosing spondylitis	0.0001	0.00139	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—ankylosing spondylitis	9.96e-05	0.00138	CcSEcCtD
Etoricoxib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	9.91e-05	0.00138	CcSEcCtD
Etoricoxib—Vision blurred—Prednisone—ankylosing spondylitis	9.85e-05	0.00137	CcSEcCtD
Etoricoxib—Urethral disorder—Methotrexate—ankylosing spondylitis	9.84e-05	0.00137	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	9.83e-05	0.00136	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	9.81e-05	0.00136	CcSEcCtD
Etoricoxib—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	9.79e-05	0.00136	CcSEcCtD
Etoricoxib—Oedema—Dexamethasone—ankylosing spondylitis	9.79e-05	0.00136	CcSEcCtD
Etoricoxib—Oedema—Betamethasone—ankylosing spondylitis	9.79e-05	0.00136	CcSEcCtD
Etoricoxib—Anaphylactic shock—Betamethasone—ankylosing spondylitis	9.79e-05	0.00136	CcSEcCtD
Etoricoxib—Insomnia—Triamcinolone—ankylosing spondylitis	9.76e-05	0.00136	CcSEcCtD
Etoricoxib—Insomnia—Methylprednisolone—ankylosing spondylitis	9.74e-05	0.00135	CcSEcCtD
Etoricoxib—Infection—Betamethasone—ankylosing spondylitis	9.73e-05	0.00135	CcSEcCtD
Etoricoxib—Infection—Dexamethasone—ankylosing spondylitis	9.73e-05	0.00135	CcSEcCtD
Etoricoxib—Feeling abnormal—Prednisolone—ankylosing spondylitis	9.67e-05	0.00134	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—ankylosing spondylitis	9.67e-05	0.00134	CcSEcCtD
Etoricoxib—Anaemia—Prednisone—ankylosing spondylitis	9.66e-05	0.00134	CcSEcCtD
Etoricoxib—Shock—Dexamethasone—ankylosing spondylitis	9.64e-05	0.00134	CcSEcCtD
Etoricoxib—Shock—Betamethasone—ankylosing spondylitis	9.64e-05	0.00134	CcSEcCtD
Etoricoxib—Dyspnoea—Triamcinolone—ankylosing spondylitis	9.62e-05	0.00134	CcSEcCtD
Etoricoxib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	9.6e-05	0.00133	CcSEcCtD
Etoricoxib—Nervous system disorder—Betamethasone—ankylosing spondylitis	9.6e-05	0.00133	CcSEcCtD
Etoricoxib—Agitation—Prednisone—ankylosing spondylitis	9.6e-05	0.00133	CcSEcCtD
Etoricoxib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	9.59e-05	0.00133	CcSEcCtD
Etoricoxib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	9.59e-05	0.00133	CcSEcCtD
Etoricoxib—Angioedema—Prednisone—ankylosing spondylitis	9.55e-05	0.00133	CcSEcCtD
Etoricoxib—Dyspepsia—Triamcinolone—ankylosing spondylitis	9.5e-05	0.00132	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—ankylosing spondylitis	9.49e-05	0.00132	CcSEcCtD
Etoricoxib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	9.48e-05	0.00132	CcSEcCtD
Etoricoxib—Eye disorder—Methotrexate—ankylosing spondylitis	9.38e-05	0.0013	CcSEcCtD
Etoricoxib—Tinnitus—Methotrexate—ankylosing spondylitis	9.35e-05	0.0013	CcSEcCtD
Etoricoxib—Anorexia—Dexamethasone—ankylosing spondylitis	9.34e-05	0.0013	CcSEcCtD
Etoricoxib—Anorexia—Betamethasone—ankylosing spondylitis	9.34e-05	0.0013	CcSEcCtD
Etoricoxib—Urticaria—Prednisolone—ankylosing spondylitis	9.32e-05	0.00129	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—ankylosing spondylitis	9.31e-05	0.00129	CcSEcCtD
Etoricoxib—Fatigue—Triamcinolone—ankylosing spondylitis	9.31e-05	0.00129	CcSEcCtD
Etoricoxib—Fatigue—Methylprednisolone—ankylosing spondylitis	9.29e-05	0.00129	CcSEcCtD
Etoricoxib—Pain—Triamcinolone—ankylosing spondylitis	9.23e-05	0.00128	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—ankylosing spondylitis	9.1e-05	0.00126	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—ankylosing spondylitis	9.06e-05	0.00126	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	9.04e-05	0.00126	CcSEcCtD
Etoricoxib—Hypertension—Prednisone—ankylosing spondylitis	9.02e-05	0.00125	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	8.92e-05	0.00124	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	8.92e-05	0.00124	CcSEcCtD
Etoricoxib—Arthralgia—Prednisone—ankylosing spondylitis	8.9e-05	0.00123	CcSEcCtD
Etoricoxib—Feeling abnormal—Triamcinolone—ankylosing spondylitis	8.89e-05	0.00123	CcSEcCtD
Etoricoxib—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	8.88e-05	0.00123	CcSEcCtD
Etoricoxib—Anxiety—Prednisone—ankylosing spondylitis	8.87e-05	0.00123	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—ankylosing spondylitis	8.87e-05	0.00123	CcSEcCtD
Etoricoxib—Insomnia—Betamethasone—ankylosing spondylitis	8.86e-05	0.00123	CcSEcCtD
Etoricoxib—Insomnia—Dexamethasone—ankylosing spondylitis	8.86e-05	0.00123	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	8.84e-05	0.00123	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	8.81e-05	0.00122	CcSEcCtD
Etoricoxib—Mental disorder—Methotrexate—ankylosing spondylitis	8.79e-05	0.00122	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—ankylosing spondylitis	8.73e-05	0.00121	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—ankylosing spondylitis	8.73e-05	0.00121	CcSEcCtD
Etoricoxib—Hypersensitivity—Prednisolone—ankylosing spondylitis	8.65e-05	0.0012	CcSEcCtD
Etoricoxib—Dyspepsia—Dexamethasone—ankylosing spondylitis	8.62e-05	0.0012	CcSEcCtD
Etoricoxib—Dyspepsia—Betamethasone—ankylosing spondylitis	8.62e-05	0.0012	CcSEcCtD
Etoricoxib—Urticaria—Triamcinolone—ankylosing spondylitis	8.57e-05	0.00119	CcSEcCtD
Etoricoxib—Urticaria—Methylprednisolone—ankylosing spondylitis	8.56e-05	0.00119	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—ankylosing spondylitis	8.55e-05	0.00119	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisone—ankylosing spondylitis	8.53e-05	0.00118	CcSEcCtD
Etoricoxib—Oedema—Prednisone—ankylosing spondylitis	8.53e-05	0.00118	CcSEcCtD
Etoricoxib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	8.51e-05	0.00118	CcSEcCtD
Etoricoxib—Decreased appetite—Betamethasone—ankylosing spondylitis	8.51e-05	0.00118	CcSEcCtD
Etoricoxib—Decreased appetite—Dexamethasone—ankylosing spondylitis	8.51e-05	0.00118	CcSEcCtD
Etoricoxib—Infection—Prednisone—ankylosing spondylitis	8.47e-05	0.00118	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	8.46e-05	0.00117	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	8.46e-05	0.00117	CcSEcCtD
Etoricoxib—Fatigue—Betamethasone—ankylosing spondylitis	8.44e-05	0.00117	CcSEcCtD
Etoricoxib—Fatigue—Dexamethasone—ankylosing spondylitis	8.44e-05	0.00117	CcSEcCtD
Etoricoxib—Shock—Prednisone—ankylosing spondylitis	8.39e-05	0.00116	CcSEcCtD
Etoricoxib—Pain—Betamethasone—ankylosing spondylitis	8.38e-05	0.00116	CcSEcCtD
Etoricoxib—Pain—Dexamethasone—ankylosing spondylitis	8.38e-05	0.00116	CcSEcCtD
Etoricoxib—Nervous system disorder—Prednisone—ankylosing spondylitis	8.36e-05	0.00116	CcSEcCtD
Etoricoxib—Skin disorder—Prednisone—ankylosing spondylitis	8.28e-05	0.00115	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—ankylosing spondylitis	8.23e-05	0.00114	CcSEcCtD
Etoricoxib—Anorexia—Prednisone—ankylosing spondylitis	8.13e-05	0.00113	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—ankylosing spondylitis	8.07e-05	0.00112	CcSEcCtD
Etoricoxib—Feeling abnormal—Dexamethasone—ankylosing spondylitis	8.07e-05	0.00112	CcSEcCtD
Etoricoxib—Feeling abnormal—Betamethasone—ankylosing spondylitis	8.07e-05	0.00112	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	8.01e-05	0.00111	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	8.01e-05	0.00111	CcSEcCtD
Etoricoxib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	7.95e-05	0.0011	CcSEcCtD
Etoricoxib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	7.93e-05	0.0011	CcSEcCtD
Etoricoxib—Urticaria—Dexamethasone—ankylosing spondylitis	7.78e-05	0.00108	CcSEcCtD
Etoricoxib—Urticaria—Betamethasone—ankylosing spondylitis	7.78e-05	0.00108	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	7.77e-05	0.00108	CcSEcCtD
Etoricoxib—Dizziness—Prednisolone—ankylosing spondylitis	7.76e-05	0.00108	CcSEcCtD
Etoricoxib—Asthenia—Triamcinolone—ankylosing spondylitis	7.74e-05	0.00107	CcSEcCtD
Etoricoxib—Abdominal pain—Dexamethasone—ankylosing spondylitis	7.74e-05	0.00107	CcSEcCtD
Etoricoxib—Abdominal pain—Betamethasone—ankylosing spondylitis	7.74e-05	0.00107	CcSEcCtD
Etoricoxib—Asthenia—Methylprednisolone—ankylosing spondylitis	7.73e-05	0.00107	CcSEcCtD
Etoricoxib—Insomnia—Prednisone—ankylosing spondylitis	7.71e-05	0.00107	CcSEcCtD
Etoricoxib—Pruritus—Triamcinolone—ankylosing spondylitis	7.64e-05	0.00106	CcSEcCtD
Etoricoxib—Cough—Methotrexate—ankylosing spondylitis	7.62e-05	0.00106	CcSEcCtD
Etoricoxib—Pruritus—Methylprednisolone—ankylosing spondylitis	7.62e-05	0.00106	CcSEcCtD
Etoricoxib—Dyspepsia—Prednisone—ankylosing spondylitis	7.51e-05	0.00104	CcSEcCtD
Etoricoxib—Chest pain—Methotrexate—ankylosing spondylitis	7.44e-05	0.00103	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—ankylosing spondylitis	7.44e-05	0.00103	CcSEcCtD
Etoricoxib—Decreased appetite—Prednisone—ankylosing spondylitis	7.41e-05	0.00103	CcSEcCtD
Etoricoxib—Rash—Prednisolone—ankylosing spondylitis	7.4e-05	0.00103	CcSEcCtD
Etoricoxib—Dermatitis—Prednisolone—ankylosing spondylitis	7.39e-05	0.00103	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	7.38e-05	0.00102	CcSEcCtD
Etoricoxib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	7.37e-05	0.00102	CcSEcCtD
Etoricoxib—Fatigue—Prednisone—ankylosing spondylitis	7.35e-05	0.00102	CcSEcCtD
Etoricoxib—Headache—Prednisolone—ankylosing spondylitis	7.35e-05	0.00102	CcSEcCtD
Etoricoxib—Constipation—Prednisone—ankylosing spondylitis	7.29e-05	0.00101	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—ankylosing spondylitis	7.19e-05	0.000998	CcSEcCtD
Etoricoxib—Dizziness—Triamcinolone—ankylosing spondylitis	7.14e-05	0.000991	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methotrexate—ankylosing spondylitis	7.13e-05	0.000989	CcSEcCtD
Etoricoxib—Dizziness—Methylprednisolone—ankylosing spondylitis	7.12e-05	0.000988	CcSEcCtD
Etoricoxib—Infection—Methotrexate—ankylosing spondylitis	7.08e-05	0.000983	CcSEcCtD
Etoricoxib—Feeling abnormal—Prednisone—ankylosing spondylitis	7.03e-05	0.000976	CcSEcCtD
Etoricoxib—Asthenia—Dexamethasone—ankylosing spondylitis	7.03e-05	0.000975	CcSEcCtD
Etoricoxib—Asthenia—Betamethasone—ankylosing spondylitis	7.03e-05	0.000975	CcSEcCtD
Etoricoxib—Nervous system disorder—Methotrexate—ankylosing spondylitis	6.99e-05	0.00097	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	6.98e-05	0.000969	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	6.97e-05	0.000968	CcSEcCtD
Etoricoxib—Nausea—Prednisolone—ankylosing spondylitis	6.97e-05	0.000968	CcSEcCtD
Etoricoxib—Pruritus—Dexamethasone—ankylosing spondylitis	6.93e-05	0.000962	CcSEcCtD
Etoricoxib—Pruritus—Betamethasone—ankylosing spondylitis	6.93e-05	0.000962	CcSEcCtD
Etoricoxib—Skin disorder—Methotrexate—ankylosing spondylitis	6.92e-05	0.000961	CcSEcCtD
Etoricoxib—Vomiting—Triamcinolone—ankylosing spondylitis	6.86e-05	0.000953	CcSEcCtD
Etoricoxib—Vomiting—Methylprednisolone—ankylosing spondylitis	6.85e-05	0.00095	CcSEcCtD
Etoricoxib—Rash—Triamcinolone—ankylosing spondylitis	6.81e-05	0.000945	CcSEcCtD
Etoricoxib—Dermatitis—Triamcinolone—ankylosing spondylitis	6.8e-05	0.000944	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—ankylosing spondylitis	6.79e-05	0.000943	CcSEcCtD
Etoricoxib—Rash—Methylprednisolone—ankylosing spondylitis	6.79e-05	0.000943	CcSEcCtD
Etoricoxib—Dermatitis—Methylprednisolone—ankylosing spondylitis	6.78e-05	0.000942	CcSEcCtD
Etoricoxib—Urticaria—Prednisone—ankylosing spondylitis	6.78e-05	0.00094	CcSEcCtD
Etoricoxib—Headache—Triamcinolone—ankylosing spondylitis	6.76e-05	0.000939	CcSEcCtD
Etoricoxib—Headache—Methylprednisolone—ankylosing spondylitis	6.75e-05	0.000936	CcSEcCtD
Etoricoxib—Abdominal pain—Prednisone—ankylosing spondylitis	6.74e-05	0.000936	CcSEcCtD
Etoricoxib—Diarrhoea—Dexamethasone—ankylosing spondylitis	6.7e-05	0.00093	CcSEcCtD
Etoricoxib—Diarrhoea—Betamethasone—ankylosing spondylitis	6.7e-05	0.00093	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	6.49e-05	0.000901	CcSEcCtD
Etoricoxib—Dizziness—Dexamethasone—ankylosing spondylitis	6.48e-05	0.000899	CcSEcCtD
Etoricoxib—Dizziness—Betamethasone—ankylosing spondylitis	6.48e-05	0.000899	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—ankylosing spondylitis	6.45e-05	0.000895	CcSEcCtD
Etoricoxib—Nausea—Triamcinolone—ankylosing spondylitis	6.41e-05	0.00089	CcSEcCtD
Etoricoxib—Nausea—Methylprednisolone—ankylosing spondylitis	6.4e-05	0.000888	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—ankylosing spondylitis	6.36e-05	0.000882	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—ankylosing spondylitis	6.34e-05	0.00088	CcSEcCtD
Etoricoxib—Hypersensitivity—Prednisone—ankylosing spondylitis	6.28e-05	0.000872	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—ankylosing spondylitis	6.27e-05	0.000871	CcSEcCtD
Etoricoxib—Vomiting—Dexamethasone—ankylosing spondylitis	6.23e-05	0.000864	CcSEcCtD
Etoricoxib—Vomiting—Betamethasone—ankylosing spondylitis	6.23e-05	0.000864	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—ankylosing spondylitis	6.2e-05	0.00086	CcSEcCtD
Etoricoxib—Rash—Betamethasone—ankylosing spondylitis	6.18e-05	0.000857	CcSEcCtD
Etoricoxib—Rash—Dexamethasone—ankylosing spondylitis	6.18e-05	0.000857	CcSEcCtD
Etoricoxib—Dermatitis—Dexamethasone—ankylosing spondylitis	6.17e-05	0.000856	CcSEcCtD
Etoricoxib—Dermatitis—Betamethasone—ankylosing spondylitis	6.17e-05	0.000856	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	6.15e-05	0.000854	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—ankylosing spondylitis	6.15e-05	0.000853	CcSEcCtD
Etoricoxib—Headache—Betamethasone—ankylosing spondylitis	6.14e-05	0.000852	CcSEcCtD
Etoricoxib—Headache—Dexamethasone—ankylosing spondylitis	6.14e-05	0.000852	CcSEcCtD
Etoricoxib—Asthenia—Prednisone—ankylosing spondylitis	6.12e-05	0.000849	CcSEcCtD
Etoricoxib—Pain—Methotrexate—ankylosing spondylitis	6.1e-05	0.000846	CcSEcCtD
Etoricoxib—Pruritus—Prednisone—ankylosing spondylitis	6.03e-05	0.000838	CcSEcCtD
Etoricoxib—Feeling abnormal—Methotrexate—ankylosing spondylitis	5.87e-05	0.000815	CcSEcCtD
Etoricoxib—Diarrhoea—Prednisone—ankylosing spondylitis	5.84e-05	0.00081	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	5.83e-05	0.000809	CcSEcCtD
Etoricoxib—Nausea—Betamethasone—ankylosing spondylitis	5.82e-05	0.000807	CcSEcCtD
Etoricoxib—Nausea—Dexamethasone—ankylosing spondylitis	5.82e-05	0.000807	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—ankylosing spondylitis	5.66e-05	0.000786	CcSEcCtD
Etoricoxib—Dizziness—Prednisone—ankylosing spondylitis	5.64e-05	0.000783	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—ankylosing spondylitis	5.63e-05	0.000782	CcSEcCtD
Etoricoxib—Vomiting—Prednisone—ankylosing spondylitis	5.42e-05	0.000753	CcSEcCtD
Etoricoxib—Rash—Prednisone—ankylosing spondylitis	5.38e-05	0.000746	CcSEcCtD
Etoricoxib—Dermatitis—Prednisone—ankylosing spondylitis	5.37e-05	0.000746	CcSEcCtD
Etoricoxib—Headache—Prednisone—ankylosing spondylitis	5.34e-05	0.000742	CcSEcCtD
Etoricoxib—Hypersensitivity—Methotrexate—ankylosing spondylitis	5.25e-05	0.000729	CcSEcCtD
Etoricoxib—Asthenia—Methotrexate—ankylosing spondylitis	5.11e-05	0.00071	CcSEcCtD
Etoricoxib—Nausea—Prednisone—ankylosing spondylitis	5.07e-05	0.000703	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—ankylosing spondylitis	5.04e-05	0.0007	CcSEcCtD
Etoricoxib—Diarrhoea—Methotrexate—ankylosing spondylitis	4.88e-05	0.000677	CcSEcCtD
Etoricoxib—Dizziness—Methotrexate—ankylosing spondylitis	4.71e-05	0.000654	CcSEcCtD
Etoricoxib—Vomiting—Methotrexate—ankylosing spondylitis	4.53e-05	0.000629	CcSEcCtD
Etoricoxib—Rash—Methotrexate—ankylosing spondylitis	4.49e-05	0.000624	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—ankylosing spondylitis	4.49e-05	0.000623	CcSEcCtD
Etoricoxib—Headache—Methotrexate—ankylosing spondylitis	4.47e-05	0.00062	CcSEcCtD
Etoricoxib—Nausea—Methotrexate—ankylosing spondylitis	4.23e-05	0.000588	CcSEcCtD
